Gamida Cell Ltd


Gamida Cell Ltd

  • Price (USD)9.25
  • Today's Change-0.590 / -6.00%
  • Shares traded709.00k
  • 1 Year change+101.97%
  • Beta--
Data delayed at least 15 minutes, as of Jan 20 2021 19:11 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies. The following are the Company's clinical pipeline products: NiCord, which is evaluated in a Phase III study in patients with high-risk blood cancers as well as in a Phase SS study in patients with severe aplastic anemia, as well as NAM-NK, an innate immunotherapy for the treatment of hematologic and solid tumors, which is investigated in a Phase I investigator-sponsored trial for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL), and multiple myeloma (MM).

  • Revenue in USD (TTM)0.00
  • Net income in USD-55.12m
  • Incorporated1998
  • Employees79.00
  • Location
    Gamida Cell Ltd5 Nahum Hafzadi StreetJERUSALEM 95484IsraelISR
  • Phone+972 26595666
  • Fax+972 26595616
  • Websitehttp://www.gamida-cell.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
SIGA Technologies, Inc.91.49m31.68m556.50m41.0017.804.9517.286.080.40390.40391.141.450.53131.444.202,231,562.0018.3933.7920.0337.2988.42--34.6254.987.385.700.00---94.3953.48-101.72--0.7308--
Xenon Pharmaceuticals Inc30.35m-26.99m559.07m100.00--3.21--18.42-0.8839-0.88390.93665.200.2036--33.38303,450.00-18.72-34.86-20.70-38.90-----91.91-593.58----0.00-----24.79-26.60---4.10--
Dynavax Technologies Corporation37.57m-96.53m561.88m231.00--8.11--14.96-1.08-1.080.39680.62890.11480.29641.71162,645.00-29.50-64.88-35.66-76.0961.19---256.92-1,063.773.47-4.270.7218--329.6026.131.91--77.54--
Ideaya Biosciences Inc8.97m-40.14m565.12m58.00--2.89--63.02-1.89-1.890.39886.720.0423----190,787.20-18.95---22.08-------447.65------0.00-------22.21------
Anika Therapeutics Inc127.54m-4.28m567.87m154.00--2.0078.654.45-0.315-0.3158.8820.020.34661.485.44828,188.30-1.1610.67-1.2311.2057.5575.00-3.3526.184.95--0.08130.008.581.6545.25-6.6312.73--
Neoleukin Therapeutics Inc0.00-28.74m567.88m36.00--2.83-----0.6472-0.64720.004.780.00----0.00-19.72-38.62-20.60-41.24-------849.49----0.0008---100.00---119.86--50.46--
Pandion Therapeutics Inc-100.00bn-100.00bn574.46m43.00--2.56----------7.62----------------------------0.00-------95.61------
Aquabounty Technologies Inc123.83k-13.70m575.82m64.00--8.04--4,650.11-0.4762-0.47620.00411.300.00244.001.831,934.84-26.72-61.88-27.71-67.47-5,304.14---11,065.05-14,904.3317.10-169.970.1278--120.94---27.41--74.70--
Poseida Therapeutics, Inc.-100.00bn-100.00bn578.64m186.00--1.96----------4.79----------------------------0.0894-------94.86------
Gamida Cell Ltd0.00-55.12m580.48m79.00--8.04-----1.17-
Spectrum Pharmaceuticals, Inc.0.00-161.59m580.77m146.00--3.45-----1.38-1.370.001.150.00----0.00-60.78-23.08-76.43-29.11-------157.04----0.00-------6.85--57.38--
BioVie Inc0.00-59.12m585.73m----40.13-----10.22-,254.85------
Molecular Templates Inc21.55m-92.35m589.08m228.00--6.98--27.34-2.03-2.030.47621.690.1641--143.16142,682.10-70.35-25.24-93.26-33.24-----428.65-89.00----0.1494--67.638.63-129.21--112.25--
Flexion Therapeutics Inc82.90m-127.58m590.06m288.00------7.12-3.09-3.091.96-0.06280.32651.032.90287,833.30-50.25-45.07-60.89-49.5179.72---153.90-600.114.31-5.971.01--223.91--11.72--37.15--
CEL-SCI Corporation558.67k-30.45m596.74m43.00--29.47--1,068.15-0.8281-0.82810.01520.50930.0164--9.49---89.27-78.89-99.96-102.92-----5,445.76-5,944.923.96-20.960.3734--20.73-3.20-36.79--105.57--
Aldeyra Therapeutics Inc0.00-39.42m601.16m20.00--7.38-----1.30-1.300.001.790.00----0.00-47.56-65.10-53.57-72.29-----------27.250.1778-------56.39---7.48--
Data as of Jan 20 2021. Currency figures normalised to Gamida Cell Ltd's reporting currency: US Dollar USD

Institutional shareholders

24.29%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Sep 20204.95m8.39%
BVF Partners LPas of 30 Sep 20202.14m3.63%
Rock Springs Capital Management LPas of 30 Sep 20202.02m3.42%
Driehaus Capital Management LLCas of 30 Sep 20201.89m3.20%
Federated Global Investment Management Corp.as of 30 Sep 20201.78m3.01%
Baker Bros. Advisors LPas of 30 Sep 2020633.32k1.07%
Alyeska Investment Group LPas of 30 Sep 2020385.19k0.65%
Millennium Management LLCas of 30 Sep 2020198.19k0.34%
ARK Investment Management LLCas of 30 Sep 2020186.42k0.32%
Meitav Tachlit Mutual Funds Ltd.as of 30 Sep 2020152.16k0.26%
More ▼
Data from 30 Sep 2020 - 30 Sep 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.